Copy number heterogeneity identifies ER+ breast cancer patients that do not benefit from adjuvant endocrine therapy.

This retrospective study of lymph-node-negative, ER+ breast cancer finds that patients identified as low risk using CNH do not benefit from adjuvant endocrine therapy.